Additionally, other gene mutations, for instance, BRAF variants have been implicated in enhancing epileptogenicity in gliomas (30) while pathways, such as RAS/MAPK and PI3K/AKT/mTOR, play significant roles in both neuronal excitability and tumor growth. This evidence concerns the gene BRAF and central nervous system cancer.